BioSpace News Archive

DBV Technologies, a clinical-stage biopharmaceutical company, announced that Daniel Tassé, Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 8:40 am ET.

Aytu BioPharma, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics, announced business and pipeline progress and reported financial results for its fiscal second quarter 2022 ended December 31, 2021.

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new long-term progression free survival (PFS) data from the Phase 3 TIVO-3 study, which compares FOTIVDA® (tivozanib) to Nexavar® (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies, are being presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced results from its ongoing Phase 2 trial of BXCL701, the Company’s investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.

Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Oakrum Pharma, LLC (“Oakrum Pharma”), in collaboration with ANI Pharmaceuticals (NASDAQ: ANIP), announce that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for a generic version of Cystadane®1 (betaine anhydrous for oral solution) Powder in a 180 gm bottle and granted Competitive Generic Therapy (CGT) of 180 days of exclusivity.

Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that positive results from the Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus abiraterone plus prednisone,

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer.

Arvinas, Inc. (Nasdaq: ARVN), today announced the presentation of new data showing that bavdegalutamide (also known as ARV-110), a novel PROTAC® protein degrader targeting the androgen receptor (AR), continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).